Emma Hall on Muck Rack

Emma Hall

Verified
As seen in: Bioanalysis Zone, The Guardian, The Lancet, JD Supra, Future Medicine, Feminist Majority Foundation, European Urology, Inkl, Personal Finance Society, Oncology Central
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Emma

Contact Emma, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Male fertility: a tough nut to crack

|
By Emma Hall Verified
| Bioanalysis Zone
Analyzing spermatozoa presents a litany of challenges, not least breaking these cells open to analyze their contents. But a new workflow has optimized this process and subsequent metabolomic analysis, ushering in a new tool for the investigation of male fertility. Utilizing a metabolomic approach, a team of researchers from the University of the Basque Country (EHU; Bilbao, Spain) have established an optimized workflow for the detection of infertility biomarkers in human spermatozoa.
Open in Who Shared Issue with article?

An author’s perspective: Augmenting immunogenicity workflows with AI and real-world evidence

|
By Emma Hall Verified
| Bioanalysis Zone
Author: Ahmad Ziad Al Meslamani, Senior Laboratory Supervisor, College of Pharmacy, Al Ain University (Abu Dhabi, United Arab Emirates). Ahmad is a dedicated scientific professional serving as a Senior Lab Supervisor at Al Ain University (AAU) in the United Arab Emirates, where he supports laboratory operations and academic activities within the College of Pharmacy.
Open in Who Shared Issue with article?

Merck’s $11.3bn deal to acquire Bio-Techne

|
By Emma Hall Verified
| Bioanalysis Zone
German science and technology group Merck (Darmstadt, Germany) has agreed to acquire US-based Bio-Techne (MN, USA), positioning it firmly in the growing life sciences market and expanding capabilities across research, diagnostics and advanced therapeutics. Valued at US $11.3 billion, the deal is aimed at accelerating Merck’s growth strategy by increasing its portfolio of research tools, analytical technologies and bioprocessing solutions.
Open in Who Shared Issue with article?
See all 140 licensed articles (142 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified